Inscripta: Sri Kosaraju

Inscripta has appointed Sri Kosaraju as its new president and CEO. Kosaraju succeeds Kevin Ness, who was the company's CEO since 2016, and who will remain as an advisor.

Kosaraju currently serves on the board of directors and is the chair of the audit committee of 10x Genomics. He also serves on the board of the nonprofit Testing for America. Prior to joining Inscripta, Kosaraju was president of Penumbra, and spent 16 years at JP Morgan, where he most recently served as head of Healthcare Equity Capital Markets and co-head of Technology Equity Capital Markets.